Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Will Pictor’s targeted proteomics platform gain traction after CDC’s hepatitis B shift? Pictor’s ViraScreen-Core test aligns with new CDC hepatitis B guidance. Find out how this multiplex assay could reshape antibody testing in clinical labs. byPallavi MadhirajuDecember 24, 2025